

R H I N O M E D

ASX Release Change of Company name and AGM Results

Change of Company Name

Melbourne, 12 November 2013. In accordance with a resolution passed by the Company's shareholders on 12 November 2013, Consegna Group Limited has changed its company name to Rhinomed Limited.

Rhinomed's new ASX codes will be RNO (Shares), RNOO (12.5 cent Options) and RNOOA (6 cent Options). The Company is currently awaiting confirmation from ASX on the date that the ASX codes will change and will advise the market by separate ASX Announcement.

AGM Results

In accordance with Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act 2001, the following information is provided to the ASX in relation to the resolutions passed by members of Rhinomed Limited at its 2013 Annual General Meeting held today. All resolutions put to the meeting were passed on a show of hands.

Resolutions	For	Against	Abstain	Proxy's Discretion*	Total Votes Received
1 Adoption of Remuneration Report	12,192,784	500,000	7,588,410	3,829,091	24,110,285
2 Change of Company name to Rhinomed Limited	20,281,194	0	0	3,829,091	24,110,285
3 Re-election of Lord Simon Reading as a Director	19,611,098	666,096	4,000	3,829,091	24,110,285
4 Approve the previous issue of 39,085,922 shares from 15% rule	20,240,194	37,000	4,000	3,829,091	24,110,285
5 Approve the issue of up to 3,809,524 Shares to Golden Five	19,574,098	666,096	41,000	3,829,091	24,110,285
6 Approve the issue of 15,250,000 Options	20,240,194	4,000	37,000	3,829,091	24,110,285
7 Approval of additional capacity to issue shares under ASX Listing Rule 7.1A	20,240,194	0	41,000	3,829,091	24,110,285

* The Chairman voted undirected proxies in his control in favour of all resolutions.

On behalf of the Board



Phillip Hains
Company Secretary

R H I N O M E D

Annual General Meeting – 12 November 2012 Speech by Chairman Mr. Martin Rogers

Welcome to the fiscal year 2012-2013 Annual General Meeting for Conseгна Group. I am Martin Rogers, your Chairman.

It gives me great pleasure to be standing here today, talking about the significant turnaround that your company has undergone in the past 9 months. With a renewed focus and a solid strategy to develop products in the respiratory and breathing management space, I am proud to not only see but also hear from shareholders and the investment community at large, that we have turned the corner and now on a fixed path of rebuilding shareholder value.

Whilst it is the work of the whole board and a team of people that puts a ship back on course in such a short space of time, it has to be led and it is with the tireless work and unwavering passion of Michael Johnson for the product and the Company that has ensured we are telling a very different story to this time last year. A new story includes the imminent release and our maiden revenues from our first product to the sports and exercise market, the TURBINE™.

After the formal proceedings of today, you will hear directly from Michael and his team on the launch of this product and how we will continue to leverage the adoption and acceptance we achieve in the sports market to tap into other high value consumer, medical and health markets. This is all designed to position the Company for long and sustained growth. I am personally very excited about the plans and glad we can share more information with you today.

One of the main outcomes of today's voting is the final step in the Company's new direction; ratifying the decision to rename the Company from Conseгна to Rhinomed. We believe that it is brand that better reflects the opportunities and the markets we are pursuing. With a platform that extends from sport to sleep, wellbeing to sleep apnea and onto drug delivery, we believe Rhinomed will be a brand that will be synonymous with nasal technology advancements in years to come.

With that being said, I also wanted to briefly touch on Vibrovein. I want to assure shareholders that whilst we maintain our focus on the respiratory and breathing management markets, we remain committed to the commercialisation of the Vibrovein technology.

R H I N O M E D

In fact, as you will hear later on, we have recently reassessed and refocused the product development process around the proposition of 'improved physician accuracy'. As a result, a new PCT application has been submitted in October, further strengthening the IP position. Along with appointing industrial designers, APS Innovations, plans for a working prototype and in vivo trials next year, we feel confident that this additional work will allow us to package the assets for future divestment to an appropriate partner. This R&D work will continue into 2014 and we will keep shareholders advised of all future developments.

Finally, as Chairman of the Board I know I can speak for my fellow directors in assuring investors that we are still committed to developing a business that in time grows in value and continues to deliver on our promise of extracting value from the assets we have. We are looking forward to a successful launch of Turbine and a very productive 2014 and thank you for your attendance.

Thank you.



Martin Rogers
Chairman
Rhinomed Limited

Certificate of Registration on Change of Name

This is to certify that

CONSEGNA GROUP LIMITED

Australian Company Number 107 903 159

did on the twelfth day of November 2013 change its name to

RHINOMED LIMITED

Australian Company Number 107 903 159

The company is a public company.

The company is limited by shares.

The company is registered under the Corporations Act 2001 and is taken to be registered in Western Australia and the date of commencement of registration is the ninth day of February, 2004.

Issued by the
Australian Securities and Investments Commission
on this twelfth day of November, 2013.



Greg Medcraft
Chairman